Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting

Abstract Objective To evaluate the relationships of lipoprotein(a) (Lp(a)) concentration and apolipoprotein(a) (apo(a)) phenotype to major adverse cardiovascular events after coronary artery bypass grafting (CABG) in long-term follow-up. Methods This single-center study included 356 patients with st...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2014-08, Vol.235 (2), p.477-482
Main Authors: Ezhov, Marat V, Safarova, Maya S, Afanasieva, Olga I, Kukharchuk, Valery V, Pokrovsky, Sergei N
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Angina, Unstable - complications
Apo(a) phenotype
Apolipoprotein(a)
Apoprotein(a) - metabolism
Atherosclerosis - etiology
Cardiovascular
Cardiovascular Diseases - etiology
Cardiovascular Diseases - mortality
Coronary Artery Bypass - adverse effects
Coronary artery bypass grafting
Coronary Artery Disease - complications
Coronary Artery Disease - surgery
Coronary heart disease
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Lipoprotein(a)
Lipoprotein(a) - blood
Long-term prognosis
Male
Middle Aged
Myocardial Infarction - etiology
Myocardial Infarction - mortality
Phenotype
Prognosis
Risk Factors
Treatment Outcome
Vein graft disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To evaluate the relationships of lipoprotein(a) (Lp(a)) concentration and apolipoprotein(a) (apo(a)) phenotype to major adverse cardiovascular events after coronary artery bypass grafting (CABG) in long-term follow-up. Methods This single-center study included 356 patients with stable coronary heart disease (CHD) who underwent successful CABG. At baseline, we assessed the patient's risk factor profile for atherosclerosis, Lp(a) concentration and apo(a) phenotype. The primary endpoint was the composite of cardiovascular death and non-fatal myocardial infarction (MI). The secondary endpoint also included hospitalization for recurrent or unstable angina and repeat revascularization. Results Over a mean of 8.5 ± 3.5 years (range 0.9–15.0 years), the primary and secondary endpoints were registered in 46 (13%) and 107 (30%) patients, respectively. Patients with Lp(a) ≥30 mg/dL were at significantly greater risk for the primary endpoint (hazard ratio (HR) 2.98, 95% confidence interval (CI) 1.76–5.03, p  
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2014.05.944